http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022085925-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb0d9a06f4c98fe19ed3db1ae100d48e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2021-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20e7fc32042956964de561c3903e8e3e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e084649f04a316827276db02bd86fd1 |
| publicationDate | 2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022085925-A1 |
| titleOfInvention | Composition comprising defensin-derived decameric peptide as active ingredient for prevention or treatment of sepsis |
| abstract | The present invention relates to a composition comprising a defensin-derived decameric peptide as an active ingredient for prevention or treatment of sepsis and, more specifically, to a pharmaceutical composition comprising the defensin-derived decameric peptide Pro10-1 or Pro10-1D as an active ingredient for prevention or treatment of sepsis or septic shock. In the present invention, Pro10-1 or Pro10-1D was identified to have an antibacterial activity against Gram-negative bacteria. Particularly, with increased cationicity and decreased hydrophobicity given thereto, Pro10-1D, which has arginine (Arg) and D-amino acid conversion added at the N-terminus thereof, was identified to decrease in toxicity, have improved permeability to negatively charged bacterial membranes, and exhibit the effects of excellent antibacterial activity, resistance to proteinases, endotoxin neutralization/clearance, and biofilm formation inhibition. Furthermore, Pro10-1D was identified to exhibit a remarkable anti-inflammatory effect by inhibiting TLR4 downstream, alleviate inflammatory insult in sepsis mouse models, and have a protective effect against organ dysfunction in sepsis mice. Thus, Pro10-1 or Pro10-1D of the present invention can find advantageous applications as a novel peptide antibiotic for effective treatment of sepsis or septic shock. |
| priorityDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 194.